Replies to post #99399 on Biotech Values

[DewDiligence]

What are the pros and cons for SNY to launch an authorized generic? On the surface, it seems like a no-brainer for them to do so.

Opinions on this are all over the map. The issues are covered at length in the ReadMeFirst.